Introduction {#s1}
============

Chronic heart failure (CHF), a clinical syndrome of left ventricular systolic and/or diastolic dysfunction, remains a major threat to public health [@pone.0107550-Remme1]. It has been estimated that there are currently over 5 million CHF patients, and more than 550,000 new patients diagnosed yearly in the USA [@pone.0107550-LloydJones1]. With the ageing of the global population, the CHF populations are increasing. Recent studies have indicated that approximately 20% of people in the world will suffer CHF at some point through their lifetime [@pone.0107550-LloydJones2]. Many CHF patients do not receive accurate diagnoses or optimum pharmacological treatments, therefore, resulting in substantial mortality and morbidity.

Although great progress has been made in diagnostic intensity and treatment, the long-term prognosis for CHF is still poor. In addition, the rising incidence of CHF is a cause for concern, and there is currently no gold standard for its diagnosis [@pone.0107550-Schocken1]. Early diagnosis and treatment are extremely important in this disease. Therefore, the development of a reliable, non-invasive biomarker is of considerable clinical importance, aiming at increasing the early detection rate of heart failure and/or predicting the progression of the disease in time.

Proteomic approaches, which could simultaneously analyze thousands of proteins and peptides, can be used to search for novel biomarkers for the early detection of the disease, their development and prognostic assessment, and the selection and monitoring of proper treatment modalities [@pone.0107550-Dawson1]. Proteomic patterns in body fluids present new opportunities for identification of novel, highly-sensitive specific markers for early detection of disease [@pone.0107550-Kaiser1]. Obviously, urine samples are derived from minimally invasive procedures in clinical analysis, and recent advances in urinary proteomics have generated interest into new potential biomarkers for various systemic diseases such as various cancers and cardiovascular diseases [@pone.0107550-Ye1], [@pone.0107550-Zimmerli1]. However, to date, easily applicable screening biomarkers for the early detection of CHF based on urine samples are lacking.

In our study, we applied two-dimensional differential gel electrophoresis (2D-DIGE) proteomic technologies to identify differentially expressed proteins in urinary protein extracts of CHF patients and healthy donors. Furthermore, we suggest that orosomucoid 1 (ORM1) is a potential novel urinary biomarker for the early detection of CHF.

Material and Methods {#s2}
====================

a) Urinary samples collection and preparation {#s2a}
---------------------------------------------

All subjects in this study were recruited from the Chinese Han population at Nanfang Hospital (Guangzhou, China) from May 2011 to August 2012. The study protocol was approved by the Nanfang Hospital Ethics Committee. All subjects were informed about the purpose of the study and gave their written consent. In all, 197 patients with CHF were confirmed according to the Framingham Heart Study (FHS) diagnostic criteria of CHF [@pone.0107550-Hunt1]. The diagnosis of CHF was based on a complete clinical evaluation, laboratory testing, echocardiography, chest X-ray, and coronary angiography, coupled with plasma amino-terminal pro-brain natriuretic peptide (NT-proBNP) content ≥1000 pg/ml. The diagnosis was conducted independently by two experienced clinicians in Nanfang Hospital, Southern Medical University. Cardiac function for each CHF patient was divided into class II, class III, and class IV according to the Cardiac Function Standard of the New York Heart Association (NYHA). The main exclusion criteria were as follows: unconscious patients; other systemic diseases such as cancer, lung disease, liver cirrhosis, bleeding disorders, severe acute infectious and metabolic disorders. 83 healthy volunteers with no evidence of disease were used as control.

The second voided clean-catch urine samples form subjects were collected in the early morning. Each urine sample (20 ml) was directly collected into a sterile plastic tube and then immediately centrifuged at 2500×g for 10 min at 4°C to remove cell debris and particulate matter. The supernatant was stored at −80°C for further analysis. Repeated freeze-thaw cycles were avoided. All the clinical data of those subjects were collected as well.

b) Proteomic analysis {#s2b}
---------------------

Equal volume urine specimens from 15 CHF patients and 15 controls were pooled respectively for 2D-DIGE analysis. Of these CHF patients, there were five cases in each NYHA class (II, III and IV). For processing, samples were first thawed on ice with the addition of protease inhibitors, 1 mmol/L phenylmethylsulfonyl fluoride, 5 mmol/L phenanthroline, and 5 mmol/L benzamidine (Sigma, St. Louis, Missouri, USA), and then centrifuged using Centricon Plus-20, 10,000 MWCO devices (Millipore, Bedford, MA, USA). Following extraction, other interfering components in the concentrated urine were removed using a 2D Clean-Up Kit (GE Healthcare, Piscataway, New Jersey, USA) according to the manufacturer\'s instructions. Protein concentration was measured with the 2D Quant Kit (GE Healtcare, Uppsala, Sweden).

Protein extracts obtained from the pooled urine samples were labeled with Cy2, Cy3 and Cy5 dyes (CyDye DIGE Fluor minimal dyes, GE Healthcare) according to the Ettan two-dimensional difference gel electrophoresis (DIGE) protocol. Briefly, 50 µg of urine protein samples from CHF patients and control group were minimally labeled with 400 pmol of Cy5 and Cy3 fluorescent dyes respectively. An internal pool was labeled with Cy2 and used to assess the reproducibility and statistical inferences. It was generated by combining equal amounts of extracts from all CHF and healthy control samples included in the study. All the labeled reactions were incubated for 30 min on ice protected from light, and then stopped by adding 1 ml of 10 mM lysine for 10 min [@pone.0107550-Jiang1]. Following the labeling reaction, all the three labeled samples were mixed and resolved in one gel.

An immobilized pH gradient (IPG) strip (24 cm, pH 3--10, nonlinear, GE Healthcare) was used for isoelectric focusing. For rehydration, samples were brought to 450 µl with rehydration buffer and 1 ml of mineral oil was added to avoid evaporation. The IPG strips were passively rehydrated overnight at room temperature. Isoelectric focusing was performed according to the protocol provided by the manufacturer (GE Healthcare) as follows: 1 h at 500 V, 1 h at 1000 V, 1 h at 5000 V, 1 h at 8000 V, then maintaining at 8000 V until a total of 60 kVh. After focusing, the strips were prepared for the second dimension gels by incubation for 15 min in equilibrium buffers I and II, respectively. Standard continuous SDS-PAGE electrophoresis for the second dimension (12%) was carried out using an Ettan DALT twelve system (GE Healthcare) until the dye front reached the bottom of the gels. Following SDS-PAGE, image scans were performed immediately using a Typhoon 9410 scanner (GE Healthcare) at the excitation emission of 488/520 nm (Cy2), 532/580 nm (Cy3) and 633/670 nm (Cy5), respectively. In addition, another strip with 1000 mg of proteins loaded was performed in parallel as a preparative gel for spots picking as marked in 2D-DIGE. The gel was stained with Coomassie Brilliant Blue [@pone.0107550-Zhao1]. Identical samples were run in three times.

After scanning, the gel images were analyzed using the DeCyder 5.01 software (GE Healthcare). Its differential in-gel analysis (DIA) module was used for pairwise comparisons of each sample with the internal standard within each gel by calculating the normalized spot volumes. The spot volumes were calculated by the background intensities combined with the borders of the spots. Spot volumes were normalized by dividing each Cy3 or Cy5 spot volume with the corresponding internal standard (Cy2). The average abundance changes for each spot across the different spot maps were calculated with the DeCyder biological variation analysis (BVA) module. The spots whose ratios of Cy5/Cy2 and Cy3/Cy2 changed by 1.5-fold or greater were regarded as differently up- or down- regulated expressed spots and were considered for further protein identification.

As described in our previous studies [@pone.0107550-Li1], [@pone.0107550-Li2], the protein spots were identified by matrix-assisted laser desorption time-of-flight mass spectrometry (MALDI-TOF/TOF-MS). Shortly, the differentially expressed protein spots were excised from the Coomassie-stained gels with an Ettan Spot Picker (GE Healthcare), and then subjected to trypsin digestion, peptide extraction and desalting. The peptide mixtures were analyzed using an ABI Voyager DE-STR mass spectrometer (ABI 4700 Proteomic Analyzer, Applied Biosystems, Foster City, CA, USA). A trypsin- fragment peak was served as an internal standard for mass calibration. A list of the corrected mass peaks was the peptide mass fingerprinting (PMF).

Protein identification using peptide mass fingerprinting was performed using the MASCOT search engine (<http://www.matrixscience.com/>, Matrix Science Ltd, London, UK) against the MSDB protein database. The search was defined as the Homo sapiens subsets of the sequences in the Swiss--Prot and NCBI nonredundant protein sequence databases. The following search parameters were used during the searche: tolerance of one missed trypsin cleavages, the errors in peptide mass were within 25 ppm for both the precursor mass tolerance and the fragments mass. Carbamidomethylation of cysteine and oxidation of methionine as fixed and variable modifications, respectively, were taken into account for database searching. The proteins matched more than four peptides and with a MASCOT score higher than 63 were considered statistically significant (*P*\<0.05). The identification results were filtered by peakErazor software (Lighthouse Data, Odense, Denmark). All matched sequences were manually validated [@pone.0107550-Li1], [@pone.0107550-Li2].

c) Bioinformatic analysis {#s2c}
-------------------------

The interaction network of differentially expressed proteins was performed automatically by STRING (Search Tool for the Retrieval of Interacting Genes/Proteins; version 8.3; <http://string.embl.de/>) with following analysis parameters[@pone.0107550-Jenssen1]: species --- Homo sapiens, confidence level --- 0.400, active prediction methods --- all. The PubGene Analysis tool (<http://www.pubgene.org/>) was used to search for literature bio-association analysis of these proteins [@pone.0107550-Jensen1]. The bio-associations had the following categories in Pubgene: Process, Function and Component. The key bio-processes related to the identified proteins were retrieved for further analysis.

d) Western blotting analysis {#s2d}
----------------------------

For western blot analyses, the samples involved six CHF patients (n = 2 in each class II, III and IV of NYHA), and six healthy controls. A total of 30 µg prepared urine proteins were separated by 12% SDS-PAGE. The gels were then transferred onto Polyvinylidene Xuoride (PVDF) (Millipore) membranes. The membranes were blocked in a solution of TBS containing 5% nonfat milk powder and 0.1% Tween-20 for 1 h at room temperature and then incubated overnight at 4°C with the monoclonal antibody against the human ORM1 protein (diluted 1∶500; Abcam, UK). After three 10-min washes in TBS-T, the membranes were incubated with horseradish peroxidase horseradish (HRP) conjugate of goat anti-rabbit IgG (Bioworld Technology, Louis Park, MN, USA) at a 1∶5000 dilution at room temperature for 1 h. The proteins were detected using an enhanced chemiluminescence (ECL, Pierce, Rockford, IL, USA) detection system. Relative intensities were documented and analyzed by densitometry.

e) Enzyme-linked immunosorbent assay (ELISA) analysis {#s2e}
-----------------------------------------------------

The concentration of ORM1 protein in urine samples was measured with a commercially available ELISA kit (R&D Systems, Minneapolis, USA) according to the manufacturer\'s instructions. The assay has a minimum detectable dose of ORM1 at 0.538 ng/ml, exhibiting linearity between 3.12 and 200 ng/ml. The standard curve was created using the suppliers\' lyophilized human ORM1. The levels of urinary ORM1 were corrected by urinary creatinine (Cr) concentrations to avoid the influence of urine volume. Thereby, the results were expressed as ORM1 -to-Cr ratio (ORM1/Cr nanograms per miligrams of creatinine). Urine creatinine (Cr) levels were measured at the Department of Clinical Laboratory of Nanfang Hospital (Guangzhou, China).

f) Statistical methods {#s2f}
----------------------

All data were collected and used for statistical analyses with SPSS software 13.0 (SPSS, Chicago, IL, USA). Values were presented as mean ± standard deviation (SD). The difference among two groups or three groups was compared with Student\'s t test or one-way ANOVA. A Spearman analysis was performed to explore the relationship between urinary ORM1-Cr and the clinical characteristics of subjects where appropriate. Univariate (nonparametric rank sum test) and multivariate (logistic regression) analyses were conducted to evaluate the relationship between urinary ORM1 expression and clinical parameters of CHF, including age, sex, diabetes, hypertension, coronary heart disease, cardiomyopathy, renal dysfunction, left ventricular ejection fraction (LVEF), NT-proBNP and NYHA classification. Receiving operating curve (ROC) analyses were used to define the most optimal diagnostic cutoff as well as the diagnostic performance given by the area under the curve (AUC), estimating the sensitivity versus its false-positive rate at optimal cutoffs. The best statistical cut-off value of ORM1-Cr was defined, which means the point at which the sum of sensitivity and specificity is more than other points. The results were considered statistically significant at *P*-value \<0.05.

Results {#s3}
=======

a) Clinical characteristics of subjects {#s3a}
---------------------------------------

[Table 1](#pone-0107550-t001){ref-type="table"} has list the clinical characteristics of all subjects in our study. There was no statistical difference in clinical characteristics (e.g. age, sex, serum creatinine and urinary creatinine). The urine samples form 15 CHF patients and 15 controls were randomly selected for 2D-DIGE analysis. Among the 15 CHF patients, there were five cases in each class II, III and IV of NYHA. Furthermore, there were 176 CHF patients and 62 healthy volunteers recruited for ELISA quantitative analysis. Of these 176 subjects with CHF, the CHF cases belonging to class II, III and IV numbered 34, 87 and 55 respectively.

10.1371/journal.pone.0107550.t001

###### Clinical data for subjects in the study.

![](pone.0107550.t001){#pone-0107550-t001-1}

                               Samples for 2D-DIGE   Samples for ELISA                 
  --------------------------- --------------------- ------------------- -------------- -----------------
                                    Controls                CHF            Controls           CHF
  Number                               15                   15                62              176
  Gender (Male/Female)                 8/7                  6/9             30/32            99/78
  Age (years)                      58.67±14.89          61.73±13.82      59.82±13.17      62.62±14.59
  Urine creatinine (mg/dl)         97.91±46.03         113.29±63.08      97.91±46.03     113.29±63.08
  Serum creatinine (umol/L)        99.72±46.57         115.47±68.94      100.63±49.29    118.45±70.57
  NT-proBNP (pg/ml)                     /             6852.12±7816.69         /         7703.96±8695.85

b) 2D-DIGE analysis and twenty differently expressed proteins were identified by MALDI-FOF/TOF-MS {#s3b}
-------------------------------------------------------------------------------------------------

[Figure 1](#pone-0107550-g001){ref-type="fig"} has shown a representative 2D-DIGE image from proteomic profiling of urine samples from patients with CHF and healthy controls. After quantitative and statistical analysis, the 28 differential protein spots with volumes changed by 1.5-fold or more were selected for further identification by MALDI-FOF/TOF-MS. These 28 differently expressed protein spots corresponded to twenty different protein accession numbers ([Fig. 1](#pone-0107550-g001){ref-type="fig"}). Seven proteins were significantly up-regulated in CHF and the other thirteen were down- regulated. The up-regulated proteins were Cadherin-1 (CDH1), Zinc-alpha-2-glycoprotein (AZGP1), Alpha-1-acid glycoprotein 1 (ORM1), Protein AMBP (AMBP), Ig kappa chain C region (IGKC), Ig lambda-1 chain C regions (IGLC1),Ganglioside GM2 activator (GM2A). The down-regulated proteins involved Uromodulin (UMOD), Kininogen-1 (KNG1), Alpha-amylase 1 (AMY1A), Vitamin D-binding protein (GC), Pancreatic alpha-amylase (AMY2A), Serum albumin (ALB), Leukocyte elastase inhibitor (SERPINB1), Inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4), Prothrombin (F2), Calbindin (CALB1), Basement membrane-specific heparan sulfate proteoglycan core protein (HSPG2), Mannan-binding lectin serine protease 2 (MASP2), CD59 glycoprotein (CD59). Information about these protein spots concerning access numbers, gene names, molecular weight, PI, total ion scores, fold changes of spots volumes and overall trends is presented in [Table 2](#pone-0107550-t002){ref-type="table"}.

![Distribution of all 28 differentially expressed protein spots in a representative two- dimensional fluorescent differential gel electrophoresis (2D-DIGE) image from proteomic profiling of urine samples from patients with CHF and healthy controls.\
Further identified protein spots are indicated by spot ID. Protein spots, protein name and spot ID are indicated (arrows).](pone.0107550.g001){#pone-0107550-g001}

10.1371/journal.pone.0107550.t002

###### Identification of differentially expressed proteins in urine from chronic heart failure and normal control.

![](pone.0107550.t002){#pone-0107550-t002-2}

  Master number    Accession No.   Gene Name   Protein molecular weight   Protein PI   Pep. Count[a](#nt101){ref-type="table-fn"}   Total ion score   Fold changes[b](#nt102){ref-type="table-fn"}   Overall trend[c](#nt103){ref-type="table-fn"}
  --------------- --------------- ----------- -------------------------- ------------ -------------------------------------------- ----------------- ---------------------------------------------- -----------------------------------------------
  117                 P07911         UMOD              72451.4               5.05                          9                              518                         −12.77±3.46                                        down
  133                 P07911         UMOD              72451.4               5.05                          9                              323                         −10.37±3.18                                        down
  279                 P12830         CDH1               97852                4.58                          3                              212                          3.15±0.29                                          up
  510                 P01042         KNG1              72995.6               6.34                          7                              263                         −2.54 ±0.33                                        down
  671                 P04745         AMY1A             58415.2               6.47                          7                              213                          −3.05±2.19                                        down
  672                 P02774          GC               54525.6               5.4                           3                              134                          −3.33±1.26                                        down
  697                 P04746         AMY2A             58354.3               6.6                           8                              106                          −2.45±1.06                                        down
  700                 P04746         AMY2A             58354.3               6.6                           8                              215                          −2.33±0.52                                        down
  822                 P02768          ALB              71317.2               5.92                          8                              208                          −4.33±0.51                                        down
  827                 P02768          ALB              71317.2               5.92                          9                              229                          −6.31±1.21                                        down
  850                 P02768          ALB              71317.2               5.92                          7                              163                          −6.24±0.89                                        down
  924                 P25311         AZGP1              34079                5.57                          5                              265                          7.31±1.54                                          up
  945                 P25311         AZGP1              34079                5.57                          4                              245                          7.55±1.89                                          up
  952                 P25311         AZGP1              34079                5.57                          6                              349                          7.46±2.27                                          up
  967                 P02763         ORM1              23724.8               4.93                          3                              302                          14.81±3.49                                         up
  978                 P30740       SERPINB1            42828.7               5.9                           5                              233                          −3.96±1.12                                        down
  1086                Q14624         ITIH4             103521.1              6.51                          4                              189                          −3.96±1.23                                        down
  1094                Q14624         ITIH4             103521.1              6.51                          5                              212                          −2.89±0.63                                        down
  1238                P02760         AMBP              39886.3               5.95                          4                              298                          5.63±2.03                                          up
  1266                P00734          F2               71474.7               5.64                          3                              167                          −4.55±1.96                                        down
  1362                P01842         IGLC1             11400.6               6.92                          1                              32                          −11.72±3.69                                         up
  1403                P01834         IGKC              11772.7               5.58                          1                              94                           17.63±5.67                                         up
  1527                P05937         CALB1             30291.1               4.7                           3                              77                           −4.09±0.86                                        down
  1529                P01834         IGKC              11772.7               5.58                          1                              50                           4.43±1.49                                          up
  1621                P98160         HSPG2             479220.5              6.06                          6                              253                          −2.89±1.34                                        down
  1675                P17900         GM2A              21280.9               5.17                          2                              152                          6.31±3.63                                          up
  1681                O00187         MASP2             77224.2               5.47                          7                              351                          −3.15±1.74                                        down
  1726                P13987         CD59               14795                6.02                          1                              59                           2.99±1.36                                         down

Calculated by amino acid count.

Fold changes of spot intensities represented as mean ± SD.

up: up-regulated in the heart failure group. down: down-regulated in the heart failure group.

c) ORM1 was indicated for further investigation based on bioinformatics analysis {#s3c}
--------------------------------------------------------------------------------

Pubgene analysis of the twenty identified proteins was performed to search for the associated bio-processes. As a result, this analysis predicted 1,600 different bio-processes to be associated with identified proteins. The top 15 closely related bio-processes included growth, induction, signal transduction, pathogenesis, secretion, catabolic process, digestion, localization, translation, coagulation, death, RNA splicing, apoptosis, phosphorylation and complement activation. Noticeably, ORM1 was predicted to play important roles in many of these 15 bio-processes such as growth, induction, signal transduction, pathogenesis, catabolic process, coagulation and phosphorylation ([Table 3](#pone-0107550-t003){ref-type="table"}). Furthermore, we observed tight connections between ORM1 and other identified proteins such as ALB, AMBP and ITIH4 from the Network based on co-occurrence in articles, which was consistent with the result by STRING 9.0 program. Those findings suggested that ORM1 was a key function partner with ALB, AMBP and ITIH4 ([Fig. 2B](#pone-0107550-g002){ref-type="fig"}), which play vital roles in the development of acute-phase reaction and inflammation indicated by Pubgene (not shown).

![Bioinformatic analysis of bio-association network by Pubgene and String programs.\
(A) Bio-process associated with the twenty identified proteins was indicated by Pubgene. (B)The ORM1 protein function partner network was indicated by String analysis.](pone.0107550.g002){#pone-0107550-g002}

10.1371/journal.pone.0107550.t003

###### Top 15 of total 1600 bio-process for the twenty identified proteins in Pubgene.

![](pone.0107550.t003){#pone-0107550-t003-3}

  Description                                                                 Associated Terms                                                      Article (*p*-value)
  ----------------------- ------------------------------------------------------------------------------------------------------------------------ ---------------------
  Growth                    ALB, AMBP, AMY1A, AMY2A, AZGP1, CALB1, CD59, CDH1, F2, GC, GM2A, HSPG2, IGKC ITIH4 KNG1, MASP2, ORM1, SERPINB1, UMOD           7.96
  Induction                ALB, AMBP, AMY1A, AMY2A, AZGP1, CALB1, CD59, CDH1, F2, GC, GM2A, HSPG2, IGKC, ITIH4, KNG1, MASP2, ORM1, SERPINB1, UMOD          3.97
  Signal transduction      ALB, AMBP, AMY1A, AMY2A, AZGP1, CALB1, CD59, CDH1, F2, GC, GM2A, HSPG2, IGKC, ITIH4, KNG1, MASP2, ORM1, SERPINB1, UMOD          3.93
  Pathogenesis             ALB, AMBP, AMY1A, AMY2A, AZGP1, CALB1, CD59, CDH1, F2, GC, GM2A, HSPG2, IGKC, ITIH4, KNG1, MASP2, ORM1, SERPINB1, UMOD          3.76
  Secretion                             ALB, AMBP, AMY1A, AMY2A, CALB1, CD59, CDH1, F2, GC, GM2A, HSPG2, ITIH4, KNG1, SERPINB1, UMOD                       3.15
  Catabolic process              ALB, AMY1A, AMY2A, AZGP1, CALB1, CD59, CDH1, F2, GC, GM2A, HSPG2, IGKC, ITIH4, KNG1, ORM1, SERPINB1, UMOD                  3.1
  Digestion                      ALB, AMY1A, AMY2A, AZGP1, CALB1, CD59, CDH1, F2, GC, GM2A, HSPG2, IGKC, ITIH4, KNG1, MASP2, SERPINB1, UMOD                2.49
  Localization                   ALB, AMY1A, AMY2A, AZGP1, CALB1, CD59, CDH1, F2, GC, GM2A, HSPG2, IGKC, ITIH4, KNG1, MASP2, SERPINB1, UMOD                2.44
  Translation                 ALB, AMBP, AMY1A, AMY2A, AZGP1, CALB1, CD59, CDH1, F2, GC, GM2A, HSPG2, IGKC, ITIH4, KNG1, MASP2, SERPINB1, UMOD             1.95
  Coagulation                              ALB, AMY1A, AMY2A, CD59, CDH1, F2, GC, HSPG2, ITIH4, KNG1, MASP2, ORM1, SERPINB1, UMOD                          1.53
  Death                          ALB, AMY1A, AMY2A, AZGP1, CALB1, CD59, CDH1, F2, GC, GM2A, HSPG2, IGKC, ITIH4, KNG1, MASP2, SERPINB1, UMOD                1.33
  RNA splicing                                                             ALB, CDH1, IGKC, IGLC1                                                           1.1
  Apoptosis                                ALB, AMBP, AMY1A, AMY2A, CALB1, CD59, CDH1, F2, GC, HSPG2, ITIH4, KNG1, SERPINB1, UMOD                          1.04
  phosphorylation                            ALB, AMY1A, AMY2A, CALB1, CD59, CDH1, F2, GC, HSPG2, IGKC, ITIH4, KNG1, ORM1, UMOD                              1
  complement activation                                             ALB, CD59, CDH1, ITIH4, KNG1, MASP2                                                    0.982

*P* =  term/total (number of records of terms according to a specific function divided by their total number of records in the MEDLINE).

d) Verification of higher urinary ORM1 levels in patients with CHF {#s3d}
------------------------------------------------------------------

To further verify our proteomic findings, we used western blotting analysis to study the expression of urinary ORM1 in individual samples from patients with CHF and control groups. The results clearly demonstrated that urinary ORM1 was significantly up-regulated in CHF cases in comparison to controls. These variations in urinary ORM1 expression were consistent with our DIGE results ([Fig. 3](#pone-0107550-g003){ref-type="fig"}).

![Verification of ORM1 protein expression in urine samples form patients with CHF and normal controls.\
(A) A 3-D view of ORM1 protein was to show the higher expression of ORM1 protein in urine of patients with CHF compared with normal controls. (B) Verification of ORM1 expression in individual urine samples of patients with CHF and normal controls by western blotting. (C) MS of in-gel trypsin digests of the protein and analysis of the depicted peptide spectrum resulted in the identification of ORM1.](pone.0107550.g003){#pone-0107550-g003}

e) Quantification of urinary ORM1 by ELISA {#s3e}
------------------------------------------

ELISA was used to quantify urinary ORM1 levels in 176 patients with CHF and 62 healthy controls. After normalization by creatinine level, the urinary ORM1 was markedly elevated in patients with CHF compared to controls (6498.83±4300.21 versus 2102.26±1069.24 ng/mg, *P*\<0.0001) ([Fig. 4A](#pone-0107550-g004){ref-type="fig"}). When the CHF patients were stratified by NYHA classification, the urinary ORM1 concentrations were 3086.24±1474.91, 6284.97±4088.02 and 8946.71±4298.05 ng/mg for CHF patients with class II, III and IV, respectively. The expression level of urinary ORM1 was positively associated with the class of CHF classification (*P*\<0.0001). The correlation indicated by the Spearman test is 0.499, suggesting that the level of ORM1 was markedly elevated in urine as heart failure worsened. In addition, the relationship between urinary ORM1 levels and the clinical characteristics of patients with CHF is presented in [Table 4](#pone-0107550-t004){ref-type="table"}. There was no significant association between the urinary ORM1 expression and other clinical features of CHF such as age, sex, diabetes, hypertension, coronary heart disease, cardiomyopathy, renal dysfunction and left ventricular ejection fraction (LVEF) except for NT-proBNP and the classification of CHF. Furthermore, the multivariate analysis suggested that the urinary ORM1 content was associated with the NT-proBNP (OR: 2.106, 95% CI: 1.213--3.524, *P = *0.002) and the NYHA classification of CHF (OR: 3.019, 95% CI: 1.329--4.721, *P*\<0.001) ([Table 5](#pone-0107550-t005){ref-type="table"}).

![Urinary ORM1 as a potential biomarker for CHF.\
(A) ELISA was used to quantify urinary ORM1 levels in 176 patients with CHF and 62 healthy controls. The expression level of ORM1 in different NYHA functional classification of CHF. \**P* \<0.05 compared with control group; \*\**P* \<0.05 compared with CHF I; \*\*\**P* \<0.05 compared with CHF III. (B) ROC curve of urinary ORM1 as a detection marker for CHF was based on a series of 238 urine samples. The optimal cut off was 2484.98 ng/mg, and the area under the ROC curve (AUC) for diagnosis of CHF was 0.892 (95% confidence interval (CI) 0.848--0.936).](pone.0107550.g004){#pone-0107550-g004}

10.1371/journal.pone.0107550.t004

###### Relationship between urinary ORM1/Cr level and chronic heart failure.

![](pone.0107550.t004){#pone-0107550-t004-4}

  Clinical features                                        Number   Urinary ORM1 levels (ng/mg)     *P*
  ------------------------------------------------------- -------- ----------------------------- ---------
  age≥65 years                                               83           6608.92±4207.72          0.750
  age\<65 years                                              93           6400.57±4401.53        
  Male                                                      108           6254.27±4292.88          0.343
  Female                                                     68           6887.25±4314.96        
  With diabetes                                              28           6284.09±4181.24          0.664
  Without diabetes                                          148           6437.29±4333.47        
  With hypertension                                          68           5894.90±3791.18          0.140
  Without hypertension                                      108           6879.08±4567.93        
  With coronary heart disease                                62           6885.65±4416.60          0.380
  Without coronary heart disease                            114           6288.45±4240.41        
  With cardiomyopathy                                        42           6033.04±3915.83          0.423
  Without cardiomyopathy                                    134           6644.82±4417.51        
  With renal dysfunction                                     31           7503.97±4472.75          0.152
  Without renal dysfunction                                 145           6283.94±4247.46        
  LVEF\<50%                                                 136           6922.04±4432.13          0.153
  LVEF≥50%                                                   40           5990.78±4106.26        
  NT-proBNP≥7704[\*](#nt105){ref-type="table-fn"} pg/ml      62           8344.42±4719.76         \<0.001
  NT-proBNP\<7704 pg/ml                                     114           5495.09±3705.04        
  NYHA II                                                    34           3086.24±1474.91         \<0.001
  NYHA III                                                   87           6284.97±4088.02        
  NYHA IV                                                    55           8946.71±4298.05        

\* The mean value of NT-proBNP in CHF patients.

10.1371/journal.pone.0107550.t005

###### The multivariate analysis of urinary ORM1/Cr level and clinical parameters.

![](pone.0107550.t005){#pone-0107550-t005-5}

  Parameter                 *p*-value(uni)   *p*-value(multi)      95% CI       OR
  ------------------------ ---------------- ------------------ -------------- -------
  Age                           0.815             0.637         0.563--1.426   1.012
  Sex                           0.567             0.346         0.852--1.639   1.156
  Diabetes                      0.342             0.266         0.899--1.963   1.818
  Hypertension                  0.459             0.501         0.603--2.507   1.962
  Coronary heart disease        0.147             0.193         0.786--3.722   2.321
  Cardiomyopathy                0.861             0.632         0.479--1.892   1.523
  Renal dysfunction             0.201             0.153         0.463--1.557   0.678
  LVEF                          0.747             0.518         0.902--1.010   0.998
  NT-proBNP                    \<0.001            0.002         1.213--3.524   2.106
  NYHA classification          \<0.001           \<0.001        1.329--4.721   3.019

f) Evaluation of urinary ORM1 as a potential biomarker for CHF {#s3f}
--------------------------------------------------------------

After quantitative measurement of ORM1 in 238 urine samples by ELISA, we applied ROC curves to assess the potential utility of urinary ORM1 in diagnosing and monitoring CHF. ROC analyses rendered an optimum cut-off value of 2484.98 ng/mg corresponding to 90.91% sensitivity and 85.48% specificity. The area under the ROC curve (AUC) of ORM1-Cr for diagnosis of CHF was 0.892 (95% confidence interval (CI) 0.848--0.936).

Discussion {#s4}
==========

The exact incidence and prevalence of CHF remain probably underestimated due to the difficulties in accurate diagnosis [@pone.0107550-Guha1]. Easily applicable screening markers for the early detection of the clinical course of CHF are currently lacking. A number of published studies have used proteomic methods to identify novel biomarkers for a variety of diseases. Notably, urinary proteomic biomarker models have recently been developed and shown potential for the accurate identification of several different disorders including ischaemic heart disease [@pone.0107550-Delles1], endometriosis [@pone.0107550-Cho1], diabetic nephropathy [@pone.0107550-SnellBergeon1] and some cancers [@pone.0107550-Ye2], [@pone.0107550-Jou1].

In our present study, we focused on the urinary proteome, because urine is easy to collect relatively large quantities using non-invasive procedures compared with other body fluids. Moreover, the clinical importance of some urinary proteins has been demonstrated not only in urogenital diseases, but also in other systemic diseases [@pone.0107550-Smith1]--[@pone.0107550-Buhimschi1]. Here, we conducted a 2D-DIGE analysis, which is an accurate quantitative comparison proteomic method, to compare the different protein expression profiles in the urine proteomes between CHF patients and healthy controls. Twenty differentially expressed proteins were identified as candidate biomarkers correlated with CHF. We further identified ORM1 as a novel CHF-related biomarker, which was significantly up-regulated in CHF patients, by bioinformatic analysis, western blotting and ELISA analyses.

Our bioinformatic analyses indicated that ORM1 played important roles in many bio-processes such as growth, induction, signal transduction, pathogenesis, catabolic process, coagulation and phosphorylation. ORM1 was also suggested to be a key function partner with ALB, AMBP and ITIH4 ([Fig. 2B](#pone-0107550-g002){ref-type="fig"}). Furthermore, inflammation was demonstrated to be associated with the pathophysiology of CHF [@pone.0107550-Bozkurt1]. ORM1 is a prominent component of the temporary proteinuria, which could be associated with exercise and acute inflammation [@pone.0107550-Andersson1]. To date, a study regarding the association between urinary ORM1 and CHF has not been reported. Thus, ORM1 was selected for further investigation in our study.

ORM1 (Orosomucoid-1, α1-acid glycoprotein 1), a single-chain polypeptide with a high carbohydrate moiety (42%) and a strong negative charge (isoelectric point, 2.7), functions as a transport protein in the bloodstream [@pone.0107550-Ito1], [@pone.0107550-Christiansen1]. It binds various ligands in the interior of its beta-barrel domain, and also binds synthetic drugs and influences their distribution and availability in the body. Human liver cells are normally the site of ORM1 production, but it can also be produced in endothelial cells and some tumor cells [@pone.0107550-Sorensson1]. Some studies have demonstrated that ORM1 could be also synthesized by lymphocytes, macrophages, monocytes and granulocytes [@pone.0107550-Andersson1], [@pone.0107550-Gahmberg1]. ORM1, a member of immunocalins family, has a regulatory dampening effect on the inflammatory cascade, thereby protecting against tissue damage from excessive inflammation [@pone.0107550-Christiansen1], [@pone.0107550-Christiansen2]. Some studies have demonstrated that the concentrations of ORM1 in plasma and urine are usually much lower than albumin, but increased in urine to concentrations equal to or higher than albumin in conditions of acute inflammation and tissue repair [@pone.0107550-Kuller1]--[@pone.0107550-Logdberg1].

To the best of our knowledge, this study is the first time that ORM1 has been identified in urine from patients with CHF by 2D-DIGE proteomic means. Our urinary proteome findings showed that the expression of ORM1 was significantly increased 14.81-fold in the CHF group compared with healthy controls. Meanwhile, the expression of elevated ORM1 in urine from CHF patients was further confirmed by western blotting. After quantitative ELISA analysis of urinary ORM1 in 238 individual samples, we observed that the levels of urinary ORM1 were elevated in CHF patients than controls, with significant difference found. Furthermore, the Spearman analysis showed that urinary ORM1 had a high positive correlation with the NYHA functional classification of CHF, indicating that the increased level of urinary ORM1 was associated with the CHF worsened, and the multivariate analysis indicated that the urinary ORM1 expression correlated with the plasma NT-proBNP (*P = *0.002) and NYHA classification (*P*\<0.001). In addition, ROC curves suggested at an optimum cut-off value of 2484.98 ng/mg with 90.91% sensitivity and 85.48% specificity respectively could be used for the diagnosis of CHF. Thus, all those results demonstrate the urinary ORM1 protein has potential value for the early diagnosis of CHF.

However, the pathophysiologic mechanisms responsible for those findings are unclear. One possible explanation could be that the increased ORM1 may be correlated with the inflammatory activation in patients with CHF. Previous studies have provided solid evidence to support a pivotal role of inflammation in the underlying pathophysiology of CHF through both animal and human research [@pone.0107550-Maekawa1], [@pone.0107550-Wrigley1]. Cytokines are mainly produced by activated monocytes and macrophages, and these inflammatory proteins have formed the basis of the CHF inflammatory paradigm. Notably, monocyte activation, which plays a core role in the inflammatory pathophysiology of CHF, results in the subsequent release of inflammatory cytokines, their migration to the myocardium, adhesion to the endothelial wall, and other complex processes of the immune system [@pone.0107550-Wrigley1], [@pone.0107550-Yin1]. It has been demonstrated that C-reactive protein levels are increased in patients with CHF and could activate monocytes and then stimulate their production of inflammatory cytokines in a dose-dependent manner. Moreover, this cytokine production is significantly enhanced in those patients with ongoing myocardial damage than in those without [@pone.0107550-Yin1], [@pone.0107550-Nakagomi1]. Thereby, we suppose that the levels of urinary ORM1, similar to the C-reactive protein, may be closely related to inflammatory condition of CHF. Further studies are needed to confirm the reasons leading to the exaggerated excretion of urinary ORM1 in CHF patients.

Most studies have investigated the levels of ORM in serum. Only recently have some studies begun to look at changes in ORM levels in the urine of patients with certain diseases. Christiansen *et al*. [@pone.0107550-Christiansen3] reported that levels of ORM were found to be significantly elevated in the urine of patients with type 2 diabetes, even in normoalbuminuric patients. Furthermore, they suggested that the increased excretion of urinary ORM could be an independent, powerful predictor of cardiovascular mortality in patients with type 2 diabetes, as determined through five years of follow-up [@pone.0107550-Gahmberg1]. Their explanation was that the elevated urinary ORM is associated with cardiovascular risk factors such as inflammation, impaired left ventricular function and endothelial dysfunction [@pone.0107550-Christiansen4]. Exaggerated excretion of urinary ORM was also found to predict preeclampsia in pregnant women with pregestational type 1 diabetes, which was probably caused by an increased local renal inflammatory response [@pone.0107550-Christiansen5]. The enhanced urinary ORM concentrations were also detected in hypertensive subjects, along with other proteins such as albumin, a-1-antitrypsin, transferrin and retinol binding proteins [@pone.0107550-LisowskaMyjak1]. In addition, Irmak S *et al*. [@pone.0107550-Irmak1] identified that ORM is significantly increased in urine samples from bladder cancer patients, particularly in those with invasive tumor stages.

Several limitations of the current study, especially about the specificity of this potential biomarker, are needed to be considered when contemplating the potential value of urinary ORM1 in early diagnosis of CHF. First, all the participants were recruited from Chinese Han populations in the same hospital. As a result, our sample must be regarded as a homogeneous cohort that may not represent the overall CHF population. Second, although we did not detect an association between urinary ORM1 levels and other clinical characteristics of CHF such as age, sex, diabetes, hypertension, coronary heart disease, cardiomyopathy, renal dysfunction and LVEF, we could not exclude the possibility that other unknown factors may affect the urinary ORM1 expression. Another point that needs to be addressed is the control group. Inflammation could lead to an elevated level of ORM, and healthy controls made up the only control group in our study, probably resulting in an overestimation of the specificity of ORM1. Therefore, our preliminary findings require further exploration through larger-scale studies with adequate control groups, in particular controls that include subjects with inflammation.

Above all, this study firstly reports the identification and validation of the significantly up-regulated protein of urinary ORM1 in CHF. The elevated urinary ORM1 levels were detected in patients with CHF than healthy controls. Moreover, urinary ORM1 expression had a high positive correlation with the NYHA functional classification of CHF. Thus, our findings suggest that urinary ORM1 could be a potential biomarker for detecting CHF. Further research is warranted to investigate the possible role of urinary ORM1 in the pathogenesis of CHF.
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